225 related articles for article (PubMed ID: 30070317)
1. LncRNA HOTAIRM1 inhibits the progression of hepatocellular carcinoma by inhibiting the Wnt signaling pathway.
Zhang Y; Mi L; Xuan Y; Gao C; Wang YH; Ming HX; Liu J
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4861-4868. PubMed ID: 30070317
[TBL] [Abstract][Full Text] [Related]
2. LncRNA H19 promotes the development of hepatitis B related hepatocellular carcinoma through regulating microRNA-22 via EMT pathway.
Li L; Han T; Liu K; Lei CG; Wang ZC; Shi GJ
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5392-5401. PubMed ID: 31298392
[TBL] [Abstract][Full Text] [Related]
3. FBXO17 promotes malignant progression of hepatocellular carcinoma by activating wnt/β-catenin pathway.
Liu FH; Cui YP; He YK; Shu RH
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8265-8273. PubMed ID: 31646557
[TBL] [Abstract][Full Text] [Related]
4. LncRNA MT1JP inhibits the malignant progression of hepatocellular carcinoma through regulating AKT.
Wu JH; Xu K; Liu JH; Du LL; Li XS; Su YM; Liu JC
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6647-6656. PubMed ID: 32633354
[TBL] [Abstract][Full Text] [Related]
5. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.
Wang Y; Yang L; Chen T; Liu X; Guo Y; Zhu Q; Tong X; Yang W; Xu Q; Huang D; Tu K
Mol Cancer; 2019 Feb; 18(1):28. PubMed ID: 30782188
[TBL] [Abstract][Full Text] [Related]
6. MiR-5692a promotes the invasion and metastasis of hepatocellular carcinoma via MMP9.
Sun SJ; Wang N; Sun ZW; Chen J; Cui HW
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4869-4878. PubMed ID: 30070322
[TBL] [Abstract][Full Text] [Related]
7. LncRNA MINCR promotes the development of liver cancer by regulating microRNA-107/β-catenin.
Li H; Yuan R; Wang H; Li C; Wei J
J BUON; 2020; 25(2):972-980. PubMed ID: 32521894
[TBL] [Abstract][Full Text] [Related]
8. LncRNA DCST1-AS1 accelerates the proliferation, metastasis and autophagy of hepatocellular carcinoma cell by AKT/mTOR signaling pathways.
Li J; Zhai DS; Huang Q; Chen HL; Zhang Z; Tan QF
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(14):6091-6104. PubMed ID: 31364110
[TBL] [Abstract][Full Text] [Related]
9. Investigating function of long noncoding RNA of HOTAIRM1 in progression of SKOV3 ovarian cancer cells.
Ye L; Meng X; Xiang R; Li W; Wang J
Drug Dev Res; 2021 Dec; 82(8):1162-1168. PubMed ID: 33939846
[TBL] [Abstract][Full Text] [Related]
10. LncRNA TP73-AS1 promotes malignant progression of hepatoma by regulating microRNA-103.
Ma CX; Gao WC; Tian L
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4713-4722. PubMed ID: 31210297
[TBL] [Abstract][Full Text] [Related]
11. LncRNA 00152 promotes the development of hepatocellular carcinoma by activating JAK2/STAT3 pathway.
Li SJ; Sui MH; Sun ZX; Zhang WW
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1038-1046. PubMed ID: 30779070
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA SUMO1P3 promotes hepatocellular carcinoma progression through activating Wnt/β-catenin signalling pathway by targeting miR-320a.
Wu S; Chen S; Lin N; Yang J
J Cell Mol Med; 2020 Mar; 24(5):3108-3116. PubMed ID: 31970876
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of LncRNA ANRIL suppresses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma.
Ma J; Li T; Han X; Yuan H
J Cancer Res Clin Oncol; 2018 Feb; 144(2):205-214. PubMed ID: 29127494
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA F11-AS1 inhibits HBV-related hepatocellular carcinoma progression by regulating NR1I3 via binding to microRNA-211-5p.
Deng Y; Wei Z; Huang M; Xu G; Wei W; Peng B; Nong S; Qin H
J Cell Mol Med; 2020 Jan; 24(2):1848-1865. PubMed ID: 31880390
[TBL] [Abstract][Full Text] [Related]
15. The role of lncRNA ANRIL in the progression of hepatocellular carcinoma.
Han W; Wang Q; Zheng L; Hong H; Yan B; Ma Y; Li X; Zhou D
J Pharm Pharmacol; 2021 Jul; 73(8):1033-1038. PubMed ID: 34111289
[TBL] [Abstract][Full Text] [Related]
16. LncRNA RUNX1-IT1 inhibits proliferation and promotes apoptosis of hepatocellular carcinoma by regulating MAPK pathways.
Yan PH; Wang L; Chen H; Yu FQ; Guo L; Liu Y; Zhang WJ; Bai YL
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8287-8294. PubMed ID: 31646558
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway.
Wang MR; Fang D; Di MP; Guan JL; Wang G; Liu L; Sheng JQ; Tian DA; Li PY
Int J Med Sci; 2020; 17(9):1224-1234. PubMed ID: 32547318
[No Abstract] [Full Text] [Related]
18. EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway.
Lei T; Zhu X; Zhu K; Jia F; Li S
Cancer Biol Ther; 2019; 20(7):1007-1016. PubMed ID: 30929558
[TBL] [Abstract][Full Text] [Related]
19. LncRNA DBH-AS1 facilitates the tumorigenesis of hepatocellular carcinoma by targeting miR-138 via FAK/Src/ERK pathway.
Bao J; Chen X; Hou Y; Kang G; Li Q; Xu Y
Biomed Pharmacother; 2018 Nov; 107():824-833. PubMed ID: 30142544
[TBL] [Abstract][Full Text] [Related]
20. TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway.
Zhang HG; Pan YW; Feng J; Zeng CT; Zhao XQ; Liang B; Zhang WW
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2003-2012. PubMed ID: 30915743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
